Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Non-small cell lung cancer neoadjuvant chemotherapy: the benefits of gemcitabine
Autore:
Van Zandwijk, N;
Indirizzi:
Netherlands Canc Inst, Dept Oncol Thorac, NL-1066 CX Amsterdam, Netherlands Netherlands Canc Inst Amsterdam Netherlands NL-1066 CX rdam, Netherlands
Titolo Testata:
ANTI-CANCER DRUGS
, volume: 12, anno: 2001, supplemento:, 3
pagine: S15 - S19
SICI:
0959-4973(200107)12:<S15:NCLCNC>2.0.ZU;2-C
Fonte:
ISI
Lingua:
FRE
Soggetto:
RANDOMIZED TRIAL; PHASE-II; PREOPERATIVE CHEMOTHERAPY; SURGERY; CISPLATIN;
Keywords:
gemcitabine; neoadjuvant chemotherapy; non-small cell lung cancer; platinum-based regimen;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Van Zandwijk, N Kweekduinweg 1, NL-2051 EK Overveen, Netherlands Kweekduinweg 1 Overveen Netherlands NL-2051 EK therlands
Citazione:
N. Van Zandwijk, "Non-small cell lung cancer neoadjuvant chemotherapy: the benefits of gemcitabine", ANTI-CANC D, 12, 2001, pp. S15-S19

Abstract

Stages of non-small cell lung cancer (NSCLC) that are potential candidatesfor surgical resection have been treated in several ways: surgery alone iscurative in only two-thirds of cases and post-operative radiotherapy (RT) provides only weak control of advanced-stage disease. Since metastatic recurrence is due to the presence of micrometastases, chemotherapy (CT) can be envisaged, even at an early stage of the disease-first with the CT/RT induction combination, which improves survival (median survival: 15 months) and the resection rate (70%). Recent studies on neoadjuvant therapy have evaluated the usefulness of different induction CT regimens. Among these, the gemcitabine/cisplatin study protocol (GC), set up in a phase II study for patients with stage IIIA N2 NSCLC, was very effective [objective response (OR):70.2%; median survival: 19 months] and should be promising for stages IB and II. Other studies involving platinum analogs have shown good OR rates inducing a high resection rate and a reduction in the spread to mediastinal lymph nodes. Major studies Eire ongoing, one of which compares GC + surgery versus surgery alone (stages IB-IIIA); the other regimen alms to evaluate GC versus paclitaxel/carboplatin as well as two induction strategies. [(C) 2001 Lippincott Williams & Wilkins.].

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 09:06:48